Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane
| Autor: | R Rigo Bonin, R Juvany Roig, XL Perez Fernandez, E. Leiva Badosa, J Sabater Riera, H Colom Codina, E. Sospedra Martínez, P Cardenas Campos, A Padullés Zamora, F Tubau Quintano, P. Alia Ramos |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Microbiology (medical) medicine.medical_specialty Continuous Renal Replacement Therapy Critical Illness medicine.medical_treatment 030106 microbiology Population Urology Microbial Sensitivity Tests 030226 pharmacology & pharmacy Meropenem Sepsis 03 medical and health sciences 0302 clinical medicine Pharmacokinetics medicine Humans Pharmacology (medical) Prospective Studies Renal replacement therapy education Aged Aged 80 and over Pharmacology education.field_of_study business.industry Middle Aged medicine.disease Anti-Bacterial Agents NONMEM Infectious Diseases Concomitant Pharmacodynamics Pseudomonas aeruginosa Female business Monte Carlo Method medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 74:2979-2983 |
| ISSN: | 1460-2091 0305-7453 |
| Popis: | Background The pharmacokinetics (PK) of antibiotics change during sepsis and continuous renal replacement therapies in critically ill patients. Limited evidence exists on the use of the oXiris® high-adsorbent membrane. Objectives To develop a PK/pharmacodynamic (PD) model for meropenem in critically ill sepsis patients undergoing continuous venovenous haemodiafiltration (CVVHDF) with the oXiris® membrane, and to design an optimal dosing regimen assessed according to the PTA. Methods A prospective, open-label, observational PK trial was performed (EUDRACT 2011-005902-30). We conducted PK studies (plasma and ultrafiltrate) for at least 24 h after concomitant administration of CVVHDF and meropenem 1 g q8h. We constructed a PK model using the non-linear mixed-effects approach (NONMEM 7.3). We evaluated the suitability of different dosage regimens using Monte Carlo simulations and calculated the PTA as the percentage of subjects achieving a given percentage of time above the MIC (fT>MIC). Results The PK of meropenem was best captured by a two-open-compartment model with zero-order input kinetics and first-order elimination. Extracorporeal CL was 7.78 L/h [relative standard error (RSE) 16.45 L/h] and central compartment V (Vc) was 24.9 L (RSE 13.73 L). Simulations showed that, for susceptible Pseudomonas aeruginosa isolates (EUCAST MIC ≤2 mg/L) and attainment of 100%fT>MIC, 500 mg q8h given as extended (EI) or continuous infusion (CI) would be sufficient. For a target of 100%fT>4×MIC, CI of 3000 mg q24h or 2000 mg q8h administered as EI or CI would be required. Conclusions We have constructed a PK model of meropenem in sepsis patients undergoing CVVHDF using the oXiris® membrane. This tool will support physicians when calculating the optimal initial dose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|